Redensyl Advanced Hair Growth Serum

In a study with 26 volunteers, testing a 3% concentration over a three-month treatment, results demonstrated a +9% anagen result, a -17% telogen result, and a reported hair-density increase. This highlights the double-blind placebo comparison and clinical hair-growth positioning.

In a 20-subject, 4% study over a three-month application period, findings demonstrated a reported reduction in telogen-hair density, an increase in anagen-hair density, and a positive change in the anagen/telogen ratio.

A randomized multicenter design study with 210 subjects evaluating a 0.2% caffeine concentration at a six-month endpoint demonstrated a 10.59% anagen-ratio improvement. The authors concluded noninferiority versus 5% minoxidil.

A laboratory hair-fibre study highlighted findings on reduced breakage, improved breakage parameters, and potential damage-repair effects on treated hair fibres.

In a pilot clinical study of women experiencing persistent hair loss, a Baicapil-containing topical serum used for 60 days produced statistically significant improvements in subjective hair-loss scores and objective assessments of thin hairs. The researchers concluded that Baicapil formulations were effective in decreasing hair loss and promoting hair growth in subjects with telogen effluvium.

In a 61-volunteer placebo comparison testing a 3% concentration across a six-month duration, findings provided supplier-reported hair-loss and density results. Efficacy testing was conducted in vivo at 3%.